(-0.46%) 5 048.42 points
(-0.98%) 38 086 points
(-0.64%) 15 612 points
(0.26%) $83.79
(-2.93%) $1.590
(0.11%) $2 345.10
(0.43%) $27.47
(1.03%) $930.00
(0.12%) $0.933
(0.19%) $10.97
(0.12%) $0.800
(0.02%) $92.18
Live Chart Being Loaded With Signals
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems...
Stats | |
---|---|
Today's Volume | 388 634 |
Average Volume | 697 933 |
Market Cap | 93.97M |
EPS | $0 ( 2024-04-01 ) |
Next earnings date | ( $0 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.61 |
ATR14 | $0.0710 (2.08%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-05 | Morisset Valerie | Buy | 17 847 | Common Stock |
2024-04-05 | Morisset Valerie | Sell | 17 847 | Stock Option (Right to Buy) |
2024-03-18 | Pimblett Emily | Buy | 40 000 | Restricted Stock Units |
2023-09-20 | Morisset Valerie | Buy | 15 297 | Common Stock |
2023-09-20 | Morisset Valerie | Buy | 5 431 | Common Stock |
INSIDER POWER |
---|
40.11 |
Last 75 transactions |
Buy: 17 601 902 | Sell: 12 020 423 |
Volume Correlation
Eliem Therapeutics, Inc. Correlation
10 Most Positive Correlations | |
---|---|
BNIXU | 0.883 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Eliem Therapeutics, Inc. Correlation - Currency/Commodity
Eliem Therapeutics, Inc. Financials
Annual | 2023 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-1.300 |
Q4 | 2023 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-0.130 |
Q3 | 2023 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-0.150 |
Q2 | 2023 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-0.190 |
Financial Reports:
No articles found.
Eliem Therapeutics, Inc.
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators